CN108552491A - 具有降三高病症功能的复方醋蛋液及其制备方法 - Google Patents
具有降三高病症功能的复方醋蛋液及其制备方法 Download PDFInfo
- Publication number
- CN108552491A CN108552491A CN201810119322.6A CN201810119322A CN108552491A CN 108552491 A CN108552491 A CN 108552491A CN 201810119322 A CN201810119322 A CN 201810119322A CN 108552491 A CN108552491 A CN 108552491A
- Authority
- CN
- China
- Prior art keywords
- vinegar
- egg
- functional component
- juice
- fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021419 vinegar Nutrition 0.000 title claims abstract description 191
- 239000000052 vinegar Substances 0.000 title claims abstract description 183
- 235000011389 fruit/vegetable juice Nutrition 0.000 title claims abstract description 112
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 44
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 41
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims description 38
- 235000013601 eggs Nutrition 0.000 claims abstract description 179
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 41
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 26
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 26
- 238000012545 processing Methods 0.000 claims abstract description 19
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 18
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 18
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 241000756943 Codonopsis Species 0.000 claims abstract description 17
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 17
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 17
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 17
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 17
- 239000009636 Huang Qi Substances 0.000 claims abstract description 17
- 241000218231 Moraceae Species 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 17
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 17
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 17
- 241000271566 Aves Species 0.000 claims abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 15
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 15
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 9
- 235000013365 dairy product Nutrition 0.000 claims abstract description 9
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 238000004659 sterilization and disinfection Methods 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 37
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 35
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 35
- 235000015203 fruit juice Nutrition 0.000 claims description 34
- 102000002322 Egg Proteins Human genes 0.000 claims description 33
- 108010000912 Egg Proteins Proteins 0.000 claims description 33
- 238000000855 fermentation Methods 0.000 claims description 32
- 230000004151 fermentation Effects 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 32
- 230000001954 sterilising effect Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 26
- 240000007594 Oryza sativa Species 0.000 claims description 25
- 235000007164 Oryza sativa Nutrition 0.000 claims description 25
- 235000009566 rice Nutrition 0.000 claims description 25
- 238000000108 ultra-filtration Methods 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 21
- 239000004302 potassium sorbate Substances 0.000 claims description 21
- 235000010241 potassium sorbate Nutrition 0.000 claims description 21
- 229940069338 potassium sorbate Drugs 0.000 claims description 21
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 20
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 17
- 240000008866 Ziziphus nummularia Species 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 17
- 210000000969 egg white Anatomy 0.000 claims description 17
- 235000014103 egg white Nutrition 0.000 claims description 17
- 239000000796 flavoring agent Substances 0.000 claims description 17
- 210000003278 egg shell Anatomy 0.000 claims description 16
- 210000002969 egg yolk Anatomy 0.000 claims description 16
- 239000011521 glass Substances 0.000 claims description 15
- 235000021357 Behenic acid Nutrition 0.000 claims description 14
- 229940116226 behenic acid Drugs 0.000 claims description 14
- 235000013355 food flavoring agent Nutrition 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 13
- -1 L-arabinose potassium sorbate Chemical compound 0.000 claims description 12
- 241000286209 Phasianidae Species 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 235000012907 honey Nutrition 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 10
- 210000004080 milk Anatomy 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 8
- 235000013339 cereals Nutrition 0.000 claims description 8
- 238000007872 degassing Methods 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 235000021552 granulated sugar Nutrition 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000002893 slag Substances 0.000 claims description 8
- 238000012859 sterile filling Methods 0.000 claims description 8
- 239000008223 sterile water Substances 0.000 claims description 8
- 239000011550 stock solution Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000003643 water by type Substances 0.000 claims description 8
- 244000241872 Lycium chinense Species 0.000 claims description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims description 7
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 235000020251 goat milk Nutrition 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 2
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 2
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 2
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims description 2
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 2
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 2
- 238000005352 clarification Methods 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 241000724115 Ziziphus lotus Species 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract description 14
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 239000004615 ingredient Substances 0.000 abstract description 5
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 56
- 230000006870 function Effects 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 201000010099 disease Diseases 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 239000000284 extract Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 230000036541 health Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 238000011031 large-scale manufacturing process Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 241001065361 Gynostemma Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 229930003944 flavone Natural products 0.000 description 8
- 235000011949 flavones Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 6
- 241000219051 Fagopyrum Species 0.000 description 6
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 6
- 235000002710 Ilex cornuta Nutrition 0.000 description 6
- 241001310146 Ilex cornuta Species 0.000 description 6
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 206010010774 Constipation Diseases 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 125000000185 sucrose group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000229143 Hippophae Species 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241001251949 Xanthium sibiricum Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000007708 morin Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical class C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L15/00—Egg products; Preparation or treatment thereof
- A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Insects & Arthropods (AREA)
Abstract
本发明公开了一种具有降三高病症功能的复方醋蛋液:通过将包括下述组分的原料加工制备而成:功能性组分、水果、禽蛋、醋、益生菌和奶制品;其中,所述功能性组分包括苦荞麦、党参、白术、茯苓、炙甘草、黄芪和丹参、桑葚、龙眼、枸杞、绞股蓝、荷叶、葛根、黄精、益智仁、枣和虫草。该产品效果良好,较为理想的具有降三高病症功能的复方醋蛋液,其口感好,且营养成分高。
Description
技术领域
本发明涉及一种具有降三高病症功能的复方醋蛋液及其制备方法。
背景技术
“三高症”是指高血压、高血糖(糖尿病)和高脂血症。它们是现代社会所派生出来的“富贵病”,可能单独存在,也可能相互关联。如:糖尿病人很容易同时患上高血压或高血脂症,而高血脂又是动脉硬化形成和发展的主要因素,动脉硬化患者血管弹性差加剧血压升高。所以,出现这三种疾患中的任何一种,后期都易形成了“三高症”。(一)高血压:高血压病是当代最常见的流行病之一,早期高血压病人可表现头痛、头晕、耳鸣、心悸、眼花、注意力不集中、记忆力减退、手脚麻木、疲乏无力、易烦躁等症状,这些症状多为高级神经功能失调所致,其轻重与血压增高程度可不一致。后期血压常持续在较高水平,并伴有脑、心、肾等器官受损的表现。这些器官受损可以是高血压直接损害造成的,也可以是间接地通过加速动脉粥样硬化性疾病产生而造成的。这些器官受损的早期可无症状,最后导致功能障碍,甚至发生衰竭。(二)高血糖:最常见的高血糖症是糖尿病。糖尿病是一种慢性、终生性疾病,是一种严重危害人体健康的常见病,由于胰岛素相对或绝对不足,使体内碳水化合物、脂肪、蛋白质等营养素代谢异常。此病可引起多种并发症,严重时可以引起全身性疾病,使人致残、致盲,甚至致死。糖尿病的症状为“三多一少”,即多尿、多饮、多食及体重下降。高血糖病人要注意控制饮食,低糖低盐,加强锻炼,如果过段时间再查血糖还是高,也应考虑用降血糖的药。(三)高血脂:高血脂是指血中胆固醇或甘油三酯过高或高密度脂蛋白胆固醇过低,现代医学称之为血脂异常。如果血脂过多,容易造成“血稠”,在血管壁上沉积,逐渐形成动脉粥样硬化,逐渐堵塞血管,使血流变慢,严重时血流中断。这种情况如果发生在心脏,就会引起冠心病;发生在脑部会出现脑中风;如果堵塞眼底血管,将导致视力下降、失明;如果发生在肾脏,就会引起肾动脉硬化,肾功能衰竭;发生在下肢,会出现肢体坏死、溃烂等。此外,高血脂可引发高血压、诱发胆结石、胰腺炎,加重肝炎、老年痴呆等疾病。要降血脂可多食用维生素C片、银杏软胶囊、液体钙之类的物质。但是目前,市场上的该类用于讲三高病症的产品还存在下述缺陷:诸如口感差,营养成分低,食用效果较为普通,或者不能够规模化生产等。
发明内容
本发明要解决的技术问题是提供一种效果良好,较为理想的具有降三高病症功能的复方醋蛋液,其口感好,且营养成分高。
本发明提供的一种具有降三高病症功能的复方醋蛋液:通过将包括下述组分的原料加工制备而成:
功能性组分、水果、禽蛋、醋、益生菌和奶制品;
其中,所述功能性组分包括苦荞麦、党参、白术、茯苓、炙甘草、黄芪和丹参、桑葚、龙眼、枸杞、绞股蓝、荷叶、葛根、黄精、益智仁、枣和虫草。
作为本发明进一步的改进:通过将包括下述组分的原料加工制备而成:
功能性组分:所述功能性组分包括第一功能性组分和第二功能性组分:所述第一功能性组分包括选自苦荞麦、党参、白术、茯苓、炙甘草、黄芪和丹参中的一种或多种的混合物;所述第二功能性组分包括选自桑葚、龙眼肉、枸杞子、绞股蓝、荷叶、葛根、黄精、益智仁、山酸枣和北虫草中的一种或多种的混合物;
水果:所述水果为包括选自苹果、山楂、橙子和沙棘中的一种或几种的混合物;
禽蛋:所述禽蛋为包括选自鸭蛋、鸡蛋和/或鹌鹑蛋中的一种或两种的混合物;
醋:所述醋为包括选自香醋、水果醋和/或米醋中的一种或两种的混合物;
益生菌:所述益生菌为选自乳酸菌和双歧杆菌中的一种或两种的混合物;及
奶制品:所述奶制品为选自牛奶和羊奶中的一种或两种的混合物。
作为本发明进一步的改进:所述第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦(5-15):党参(1-8):白术(0.5-5):茯苓(1-9):炙甘草(0.5-5):黄芪(5-20):丹参(1-10);
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚(20-35: 龙眼肉(25-40):枸杞子(15-45):绞股蓝(10-30):荷叶(5-20):葛根 (5-20):黄精(5-20):益智仁(5-20):山酸枣(2-12):北虫草(10-30);
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为米醋。
作为本发明进一步的改进:所述第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦12:党参4:白术3:茯苓4:炙甘草2:黄芪10:丹参 6;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚25:龙眼肉30:枸杞子25:绞股蓝15:荷叶12:葛根10:黄精10:益智仁10:山酸枣8:北虫草18。
本发明还提供一种产品品质良好的适于规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量8-10倍水进行回流提取2-5次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温20-25℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡 24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为(60~80):(15~30):(5~10),于20MPa下均质;将均质后的混合原料于55~80℃下,杀菌2~30min,冷却至40~45℃;在冷却后的混合原料中加入的益生菌菌粉,并于40~45℃下培养发酵3~6h;
3)将醋与发酵后的发酵混合液按质量比0.5~2:1的比例混合,在25~35℃条件下,放置2~4天后,用无菌水稀释1~5倍。
4)水果原液的制作工艺:
a)将果汁加热温度55~58℃处理1~3min后过滤超滤,灌装机过滤;b) 澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于50到60℃水中5min进行脱气,然后旋紧盖子准备杀菌; d)杀菌将封盖后的果汁放入60°的水域中进行加热,10~20min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
作为本发明进一步的改进:在步骤2)中,还包括预处理工艺:所述消毒采用75%酒精擦拭或采用浓度为10mg/kg的氯水中浸泡10min消毒。
作为本发明进一步的改进:所述步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1: 6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为 3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为 20-40℃,保持压力20-30MPa,均质时间10-20min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
作为本发明进一步的改进:所述步骤5)中还包括调味剂添加,所述调味剂为选自蔗糖、葡萄糖、乳糖、果糖、山梨糖醇和甘露糖醇中的一种或几种的混合物。
作为本发明进一步的改进:所述米醋为9°纯粮米醋。
作为本发明进一步的改进:所述步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。
与现有技术相比,本发明提供的一种具有降三高病症功能的复方醋蛋液及其制备方法具有以下专利法意义的有益效果:
内含丹参提取物具有丹酚酸和迷迭香酸等抗氧化成分,丹酚酸有很强的抗氧化作用,能有效清除人体内的氧自由基,抑制脂质过氧化反应,提高人体免疫机能,其作用强度高于维生素C、维生素E、甘露醇,是目前已知的抗氧化作用最强的天然产物之一;此外,丹酚酸还具有活血化瘀,通经活络之功效,有效改善人体心脑血管动脉粥样硬化、心脏缺血、血管内皮增厚等症状,在抗肝脏纤维化、抗肿瘤以及抗衰老等方面也起到明显作用。整体调和好的组方,对以下几个方面的作用
1、脑血管系统疾病作用
内专家研究表明沙棘总黄酮治疗冠性病、绞痛脏功能强作用具明显抗律失作用沙棘黄酮及其性物质具降低高血压、软化血管、改善血循环、缺血性脑血管疾病防治缓解作用、具改善脑供血供氧,可用于治疗心律失调,心绞痛,心肌梗塞等对心血管系统症。合方中含有苦荞生物类黄酮所富含的芦丁等具有扩张血管的作用,槲皮素、桑色素等能够改善血管平滑肌的收缩、舒张功能。
免疫系统类抵御外界自身各种致病素伤害防线现代医研究表明:体衰与许疾病发及体内物质氧化作用关防止氧化及清除体内氧化产羟自由基及流行性氧自由基抗衰关键沙棘黄酮直接捕获超氧自由基羟自由基作用V-E、V-C、超氧化物歧化酶(SOD)抗氧化作用、清除体内自由基增加免疫功能调节免疫性细胞利于提高体抗病能力、延缓体衰见沙棘效具清除体内自由基作用提高免疫功能于提高体抗病能力、延缓体衰着重要作用另外沙棘富含种物营养护理皮肤、防皱抗衰作用
2、对内分泌系统的作用
(1)、降血糖作用配方中含有苦荞生物类黄酮能够促进胰岛β细胞的恢复,降低血糖和血清胆固醇,改善糖耐量,对抗肾上腺素的升血糖作用,同时它还能够抑制醛糖还原酶,因此可以治疗糖尿病及其并发症。
(2)、降血脂作用
方中苦荞生物类黄酮中所富含的槲皮素等能降低甘油三酯,总胆固醇,减少动脉粥样硬化指数。
3、抗辐射抗炎肌促组织再作用
配方中沙棘的药用价值对血液的作用,方中提取物富含VE胡萝卜素类胡萝卜素饱脂肪酸等等促进机体新陈代谢增强抗炎作用促进溃疡愈合沙棘临床辐射损伤、烧伤、阴道粘膜炎、宫糜烂、胃十二指肠溃疡均良疗效加咽喉炎、扁桃腺炎、颌窦炎、牙周炎等手术伤口愈合消除疼痛等作用。抗菌、抗病毒作用,据研究证实,苦荞生物类黄酮所富含的槲皮素、桑色素、莰非醇有抑菌和抗病毒作用。临床应用该黄酮,对各种原因引起的溃疡有祛腐生肌,消炎镇痛的奇特疗效。
4、呼吸系统疾病预防保健作用
组方在传统医学理论具止咳祛痰、消食化滞、血化瘀作用慢性咽炎支气管炎咽喉肿痛哮喘等呼吸道疾病作用沙棘含黄酮类化合物消炎促进毛细血管血液循环关
5、消化系统疾病治疗作用
由于组方中含量氨基酸机酸等种营养氯原酸其酚类化合物促进胃酸物合刺激胃液泌,同时具又消食化滞健脾养胃疏肝利器作用消化良腹胀痛胃炎及十二指肠溃疡肠炎慢性便秘均良作用
6、肝脏等保健作用
组方中含水量苹梭、草酸等机酸具缓解抗素其药物毒性作用保护肝脏,卵磷脂等磷脂类化合物种物性较高促进细胞代谢改善肝功能抗脂肪肝抗肝硬化另外对肾脏、肝脏、肺脏及骨髓均明显保护作用
7、健脑益智促进童发育作用
组方中含种氨基酸种维素、微量元素、饱脂肪酸(EPA DHA)童智力发育及身体均促进作用期服用三清扶正醋蛋液童智力水平、反应能力及保持旺盛精力体力均良作用
8、抗衰、美容护肤作用
组方中沙棘总黄酮直接捕获超氧自由基羟自由基作用VE、VC、超氧化物歧化酶(SOD)能抗氧化作用、清除体内自由基同增强免疫功能调节免疫性细胞、利于提高体抗病能力、延缓体衰沙棘富含种物营养份护理皮肤防皱抗衰作用。方中苦荞,又称鞑靼荞麦,营养极其丰富,也是有较好药用价值的药用作物。苦荞中的蛋白质主要是谷蛋白,水溶性清蛋白和盐溶性球蛋白等。其氨基酸总含量为107%,18种氨基酸齐全,总含量达11.82%,苏氨酸0.4178,缬氨酸0.5093, 蛋氨酸0.1834,亮氨酸0.7570,赖氨酸0.6884,色氨酸0.1376,异亮氨酸0.4542, 苯丙氨酸0.5413,均高于小麦粉、大米和玉米。并含有9种脂肪酸,对幼儿有促进生长发育的作用,对成年人可防止冠心病的发生。抗氧化作用:抑制油脂自动氧化中3-OH,5-OH,4-羰基和2,3位的双键起主导作用。抑制油脂氧化的能力槲皮素>桑色素>芦丁。方中苦荞麦中医学上普遍认为,苦荞麦具有清热降火、消食化滞、凉血消肿等保健作用。苦荞麦除具有荞麦的营养价值外,还有独特的保健功能。苦荞麦中含有一种特殊的类黄酮物质——芦丁,这种物质能维持血管壁的正常透性与脆性,软化血管,有促进伤口愈合、消炎、抗过敏、止咳、平喘、降血脂的作用。苦荞麦中还有一种疗效成分——维生素E,它具有较强的抗氧化作用,可抑制和消除人体内过剩的自由基,活化巨噬细胞,消除皮肤的色素沉积,增强人体免疫机能,减轻抗癌药物的负作用。组方中的膳食纤维能促进有毒物质的排泄,降低血清的总胆固醇及LDL胆固醇的含量。组方中的活性元素硒在人体内可与金属结合形成一种不稳定的"金属—硒—蛋白"复合物,有助于体内有毒物质的排除。本发明组方纯天然,无公害。药食两用,富含芦丁,具有降脂、降压、降血糖,含抑制黑色素生长的尼克酸,具有让肌肤更水嫩,更美白的神奇功效。同时能降血压、血糖、血脂,改善微循环等,又称三降食品。
9、抗肿瘤、抗癌作用
醋蛋液使蛋黄蛋清中含有的大分子营养物质破裂为小分子,释放出大量抗癌物质、深菌酶和卵磷酶、生物素等,易被人吸收。组方中沙棘物性白青花素、苦木素、香豆素、5—羟色胺等具明显抗癌性及抗癌作用体内癌细胞具定抑制杀伤阻断致癌素作用且通提高癌症患者自身免疫力减轻放疗或化疗毒副作用促进癌症患者康复特别胃癌食道癌直肠癌肝癌等消化系统癌症效比较明显。抗癌、防癌作用。苦荞生物类黄酮所富含的槲皮素等黄酮类化合物主要通过三个途径达到抗癌、防癌作用,即抗自由基作用,直接抑制癌细胞生长,抗致癌因子。鞑靼荞生物类黄酮所含的五羚基黄酮是防癌、抗癌、治优选药物。
此外,该醋蛋液含有较高的小分子蛋白质、多肽和氨基酸等,易被人体消化吸收,能够较好的提高人体的免疫力;其中添加了健脾化湿的功能性成分,能有效的促进人体的胃肠蠕动,促进消化吸收,从而达到保健的目的;制备方法简单易行、口感较好、且性状稳定,不易形成沉淀,有利于进行大规模的生产和销售。
附图说明
图1是本发明提供的一种具有降三高病症功能的复方醋蛋液的制备方法中沙棘处理过程图。
图2是本发明提供的一种具有降三高病症功能的复方醋蛋液的制备方法中的沙棘萃取工艺流程图。
图3是本发明提供的一种具有降三高病症功能的复方醋蛋液的制备方法沙棘实际操作流程图。
图中:P201烃泵;P202果汁泵;P203真空泵;P204压缩机;101:萃取罐; 102:蒸发罐;103:暂存罐;104:溶剂罐;105:缓冲罐;106:冷凝罐;
具体实施方式
以下通过实施例进一步说明本发明。应该理解的是,这些实施例是本发明的阐释和举例,并不以任何形式限制本发明的范围。
中医学自古以来有药食同源的记载。《黄帝内经太素》有云:“空腹食之为食物,患者食之为药物。”这一理论认为:许多食物既是食物也是药物,食物和药物一样同样能够防治疾病,只是功效不同而已。传统中医学认为人体发病多因虚症而起,继而正气不足,气血虚弱而发病。《黄帝内经》特别强调:“正气存内,邪不可干”这句话概括了中医养生的法则及中医的病理和医理。正气足了,人就不会得病。无论防病治未病还是治已病,皆依此理。
1、本方共18味药食同源地道中药材,又称“三清扶正十八罗汉方”。
方剂组成:
苦荞麦、党参、白术、茯苓、炙甘草、黄芪、桑葚、龙眼肉、枸杞子、丹参、绞股蓝、荷叶、葛根、黄精、益智仁、山酸枣、北虫草、沙棘。
【方解】本方治证系,饮食劳倦,脾胃虚弱,运化乏力,以致脾胃气虚,气血不足引起的诸症。方中重用苦荞麦宜补中益气,扶正固表,为君药。配伍四君子(人参换做党参、白术、茯苓、炙甘草)共奏健脾利湿为臣药,与黄芪合用,以增强益气健脾之力,桑葚、龙眼肉、枸杞子补益肝肾,扶正气之功。方中特用丹参,有活血祛瘀,养血安神之效。《神农本草经》始载:色:赤,味:苦,性:微寒,归心、肝经。“一味丹参功同四物。”语出妇人明理论。引用沙棘配伍此方,色:黄,味:酸,性:温,归肺、心经,具止咳化痰,健胃消食,活血散瘀之效。加绞股蓝,性:寒,味:甘,益气安神,民间称其为神奇的不老长寿药草,星火计划中将其列为名贵中药材首位,佐以丹参之功。黄精、益智仁,强筋骨,益智生髓,促使气血生化之源。山酸枣味甘,平,镇静安神好睡眠;《神农本草经》早有记载,山酸枣安五脏,轻身延年。荷叶为走卒,通达血脉;清香,升散,健脾升阳,葛根解肌透疹,生津止渴,辅助荷叶之效。此方诸药合用可舒经活络,扶正气,强肝肾,健脾胃,益肠道。
醋蛋液组方:9°纯粮米醋、乌鸡蛋、鹌鹑蛋、蜂蜜。
【方解】从中医学阐述:认为,食醋性温,味酸苦,有开胃、养肝、散瘀、止痛等功效。鸡蛋味甘,性平,有补中益气、养阴定惊等作用。蜂蜜味甘,性平,可补中、润燥、止痛、解毒。四者合用,可以滋阴养肝、补中开胃。古代医家采用醋蛋治疗咽疼、心绞痛、胃疼等多种疾病。
本发明为管氏三清扶正方结合醋蛋液合成复方,其功效从现代医学分析醋浸泡的禽蛋即醋蛋,无论国内外都是传统的食疗保健品,是具康复、治疗和预防三效合一的健康饮品。醋蛋液不但同时具备了醋、鸡蛋、鹌鹑蛋及饮用时加入蜂蜜的所有营养成分和食疗作用,而且在制作醋蛋过程中,鸡蛋中的蛋清在酸性条件下降解,生成了具有生物学活性的低分子量的氨基酸及寡肽,从而使其中的醋、鸡蛋及蜂蜜的食疗功能被醋蛋液可以治疗中老年人的骨质疏松,并通过钙的吸收来防治高血压。从发明人二十多年临床经验和诸多专家学者研究发现,醋蛋液作为天然保健制品的醋蛋液,长期服用是安全的。而传统的醋蛋液其具有质量不稳定、保质期短、服用不方便等缺点。
1、管氏三清扶正方利用发酵超滤浸膏浓缩技术,通过高速离心技术、超滤技术、浓缩技术等制药技术降低了药物的水分,使其体积减小到原饮片的1/10,延长了药物的保质期,传统制法把一定比例的整体复方方中药材加水十倍量,煎煮一小时,过滤,药渣再加水八倍量,煎煮三十分钟,过滤,合并煎液,加热挥发去多余水分,待有一定粘度的时候取木糖醇适量,加少量水,加热溶解,后加到刚才的药膏里,继续加热到那个膏点在纸上不湮的时候就可以了得到适合的膏剂。浸膏剂因为不含或含极少量的溶剂,有效成分比较稳定,相较于汤剂,浸膏剂保存时间较长,但浸膏剂具有很强的吸湿性,尤其是干浸膏,因而需要置于遮光容器内密闭储藏。复方浸膏剂使治疗范围更加广泛,并且使组方中的各味药物集于一体,便于服用,利于储存。稠浸膏的含水量一般为15%~20%,因其溶剂量较低,可久贮。浸膏剂每克相当于原料药2~5g,克服了汤剂给药体积较大、储存不便的缺点,浸膏剂既确保了汤剂中的有效成分,又克服了汤剂需煎煮和给药体积较大的缺点,通过水提醇沉等精制方法,可以减少药物的服用量,降低吸湿性。同时浸膏剂增加了单位体积药物的有效成分,减少了药量,提高了疗效溶剂将药材的有效成分浸出或加水煎煮,固液分离后浓缩干燥而制成的浸膏剂型;稠浸膏的含水量一般为15%~20%,因其溶剂量较低,可久贮。浸膏剂每克相当于原料药2~5g,克服了汤剂给药体积较大、储存不便的缺点,浸膏剂既确保了汤剂中的有效成分,又克服了汤剂需煎煮和给药体积较大的缺点,通过水提醇沉等精制方法,可以减少药物的服用量,降低吸湿性。同时浸膏剂增加了单位体积药物的有效成分,减少了药量,提高了疗效。
沙棘果利用低温萃取技术,在低温下,根据相似相溶原理用溶剂把一种物质从另一种物质中提取出来。该技术是由结合剪力与振动力效应之低温萃取技术、复合式微波萃取技术和超临界二氧化碳萃取分离技术三项技术所整合而成,可根据原物料之特性与产品需求进行组合调整,具有高效率、环保、安全与确保有效成分活性等优点,操作温度低于50℃,可确保天然物中有效成分的活性,不使用有害人体之溶剂,以经济的方式进行萃取分离,可充分保留其有效成分与香气,该技术具有其重要性与前瞻性。传统压榨方法的主要缺点是:压榨法无残留,但果汁收率低,不能保证无菌,色度深。有机溶剂萃取沙棘汁,收益率高,但残留溶剂有毒,不能完全去除,影响了沙棘油的质量。超临界CO萃取沙棘汁技术生产成本昂贵,无法规模化生产。亚临界低温萃取技术,是将溶剂控制在气态、液态之间的两种状态,即亚临界状态。在这种状态下,沙棘汁溶解度最大,能将油溶性的物质提取出来,其成功地克服了上述3种方法的缺点,具有工艺流程简单、操作方便、萃取效率高、产品无残毒的特点,能更容易、更彻底地与萃取物分离。无毒,在生产过程中不破坏沙棘果和籽的任何有效成份,既保证了产品质量,又不会造成环境污染。
醋蛋液发酵技术:采用国际高端生物制剂技术接种-发酵-浓缩-而来,其中嗜酸乳酸杆菌和动物双歧杆菌可以补充有益菌,能提高人体免疫力、平衡人体肠道菌群,改善人体肠道内环境,同时辅助清洁人体内部毒素起到改善便秘,提亮肤色、淡化面斑,美容养颜的效果。利用小型全自动发酵罐,将中药微粉与菌种加入发酵罐,进行发酵,等于把发酵工厂搬到了养殖场,利用中草药及活性有益菌的共同作用。发酵液态,是模拟中药在人体内的消化分解过程,采用现代生物工程技术,在人体外建立一个"工业化肠胃系统",采用人体肠道内的多种益生菌,对醋蛋进行预消化、分解和转化,把大分子的中间物质,分解转化成为能够被直接吸收的有效小分子物质。因此,发酵醋蛋疗效快、效果确切。发酵醋蛋经过预消化和转化。彻底解除液态中有害毒性,并去除了传统醋蛋汤剂"酸涩和蛋腥味"的缺陷,口味好转,患者可以长期服用。
综上述:把制备好的管氏三清扶正中药浸膏和低温萃取获得的沙棘汁有机的结合醋蛋液,形成一定比例的合方。在传统“醋泡蛋”基础上,得到RSP(核糖核酸活性蛋白激酶),再结合现代特殊工艺低温发酵配制而成的一种复合酵素。内含活性胶原蛋白多肽是通过对胶原蛋白链酶法水解,然后进行提取,变成可溶解性的水解胶原蛋白,是片段的,但保存了具立体活性的三螺旋多肽结构,即超螺旋结构闭胶原蛋白肽独特的三重螺旋结构,使其分子结构非常稳定,易吸收,且能被靶向输送到皮肤,喝出水润肌肤。现代营养学认为,米醋中含有多种有机酸、氨基酸、微量元素和维生素,鸡蛋中则含有丰富的蛋白质和卵磷脂,蜂蜜以葡萄糖和果糖为主,也含有大量氨基酸、矿物质等营养物质。研究发现,醋蛋液可以降血脂,增强机体抗自由基的作用,对预防动脉硬化有帮助,也有一定的通便、降低体重、提高免疫和抗疲劳作用。醋蛋液提供的营养物质,有助于机体内的细胞再生、分裂、软化血管,增进血液循环,有利于体内基础代谢和物质代谢的正常运行,增强免疫力和抗体效应。它的重要作用是扶正固体,增强体质,有利于抗病,因而无形显示出保健与治病作用。可以认为醋蛋液是减缓衰老,延年益寿的保健饮料。在医疗作用上具有:供营养,助消化,促吸收,清热解毒,活血化淤,化痰祛湿,舒筋活络,杀菌等。所以说,管氏三清扶正醋蛋液比常见的醋蛋液更加有效果。经现代中医研究发现,将这些功效性药食同源材料经独特的工艺发酵后取得的酵素,可以提高功效4-28倍。酵素又称为"酶",酶是各种生物化学反应的催化剂,酶能激活营养细胞,修复受损细胞,强化细胞功能,使细胞健康繁殖。通过发明人管长生先生技术萃取的植物蛋白激酶,可以激活RNA核糖核酸运转,启动RNA遗传密码,干扰基因和细胞突变,抑制和消除变异细胞,迅速活化细胞新陈代谢,加速细胞修复能力。使缓激肽的失活减少,从而达到抑制血压升高,预防及治疗高血压的目的。根据服用后的信息反馈,其医疗作用,可以预防癌变,防治高血脂症,降低高血压,防治动脉硬化和动脉粥样硬化,以及冠心病、心绞痛、心肌梗塞、脑血栓、脑出血、瘫痪、糖尿病、肝脏疾病、胆囊炎、胆结石等内外科疾病70多种。甚至对于一些难治的顽疾,也产生较好的疗效。管氏三清扶正醋蛋液含有多种复合酵素、胆碱、氨糖、低聚糖、小分子活性肽等多种人体健康不可缺少的成份,磷脂复合物可以提高人体对天然活性成分的吸收,并优化其生物有效性。所以管氏三清扶正醋蛋液在重大疾病和疑难杂病方面有很好的食疗效果。
实施例1
本实施例的具有降三高病症功能的复方醋蛋液,其中:通过将包括下述组分的原料加工制备而成:
功能性组分:所述功能性组分包括第一功能性组分和第二功能性组分:第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦5:党参1:白术0.5:茯苓1:炙甘草0.5:黄芪5:丹参1;所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚20:龙眼肉25:枸杞子15:绞股蓝10:荷叶5:葛根5:黄精5:益智仁5:山酸枣2:北虫草10;
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为米醋;所述奶制品为牛奶。
本实施例的品质高且可实现规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量8倍水进行回流提取2次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温20℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为60:15:5,于20MPa下均质;将均质后的混合原料于55℃下,杀菌2min,冷却至40℃;在冷却后的混合原料中加入的益生菌菌粉,并于40℃下培养发酵3h;
3)将醋与发酵后的发酵混合液按质量比0.5:1的比例混合,在25℃条件下,放置2天后,用无菌水稀释1倍。
4)水果原液的制作工艺:
a)将果汁加热温度55℃处理1min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于50到60℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,10min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
在步骤2)中,还包括预处理工艺:所述消毒采用75%酒精擦拭消毒。
步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1: 6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为 3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为 20℃,保持压力20MPa,均质时间10min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
步骤5)中还包括调味剂添加,所述调味剂为选自果糖、山梨糖醇和甘露糖醇的混合物。米醋为9°纯粮米醋。
步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。工艺流程请参看图1-3所示。
实施例2
本实施例的具有降三高病症功能的复方醋蛋液,其中:通过将包括下述组分的原料加工制备而成:
功能性组分:包括第一功能性组分和第二功能性组分;第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦12:党参4:白术3:茯苓4:炙甘草2:黄芪10:丹参6;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚25:龙眼肉30:枸杞子25:绞股蓝15:荷叶12:葛根10:黄精10:益智仁10:山酸枣8:北虫草18;
所述水果为苹果;所述禽蛋为鹌鹑蛋;所述醋为水果醋;所述奶制品为羊奶。
本实施例的品质高且可实现规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量10倍水进行回流提取5次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温25℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、羊奶、白砂糖进行混合,混合的比例为80:30:10,于20MPa下均质;将均质后的混合原料于80℃下,杀菌30min,冷却至45℃;在冷却后的混合原料中加入的益生菌菌粉,并于45℃下培养发酵6h;
3)将醋与发酵后的发酵混合液按质量比2:1的比例混合,在35℃条件下,放置4天后,用无菌水稀释5倍。
4)水果原液的制作工艺:
a)将果汁加热温度58℃处理3min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于60℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,20min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
在步骤2)中,还包括预处理工艺:所述消毒采用浓度为10mg/kg的氯水中浸泡10min消毒。工艺流程请参看图1-3所示。
实施例3
本实施例的具有降三高病症功能的复方醋蛋液,其中:通过将包括下述组分的原料加工制备而成:
功能性组分:包括第一功能性组分和第二功能性组分,第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦7:党参2:白术2:茯苓6:炙甘草2:黄芪8:丹参3;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚22:龙眼肉30:枸杞子20:绞股蓝15:荷叶8:葛根8:黄精8:益智仁8:山酸枣7: 北虫草12;
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为香醋。
本实施例的品质高且可实现规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量5倍水进行回流提取3次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温21℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为65:18:7,于20MPa下均质;将均质后的混合原料于60℃下,杀菌5min,冷却至41℃;在冷却后的混合原料中加入的益生菌菌粉,并于42℃下培养发酵5h;
3)将醋与发酵后的发酵混合液按质量比1:1的比例混合,在27℃条件下,放置3天后,用无菌水稀释2倍。
4)水果原液的制作工艺:
a)将果汁加热温度56℃处理2min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于55℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,12min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
在步骤2)中,还包括预处理工艺:所述消毒采用75%酒精擦拭消毒。
步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1: 6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为 3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为 22℃,保持压力21MPa,均质时间15min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
步骤5)中还包括调味剂添加,所述调味剂为选自蔗糖。
米醋为9°纯粮米醋。
步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。工艺流程请参看图1-3所示。
实施例4
本实施例的具有降三高病症功能的复方醋蛋液,其中:通过将包括下述组分的原料加工制备而成:
功能性组分:所述功能性组分包括第一功能性组分和第二功能性组分:
第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦9:党参3:白术4:茯苓7:炙甘草1:黄芪18:丹参5;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚22:龙眼肉30:枸杞子33:绞股蓝12:荷叶8:葛根8:黄精9:益智仁15:山酸枣 10:北虫草12;
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为米醋。
本实施例的品质高且可实现规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量7倍水进行回流提取2-5次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温22℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为77:25:8,于20MPa下均质;将均质后的混合原料于70℃下,杀菌15min,冷却至43℃;在冷却后的混合原料中加入的益生菌菌粉,并于43℃下培养发酵5h;
3)将醋与发酵后的发酵混合液按质量比1.5:1的比例混合,在27℃条件下,放置3天后,用无菌水稀释2倍。
4)水果原液的制作工艺:
a)将果汁加热温度56℃处理2min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于60℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,20min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
在步骤2)中,还包括预处理工艺:所述消毒采用75%酒精擦拭或采用浓度为10mg/kg的氯水中浸泡10min消毒。
步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1: 6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为 3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为 35℃,保持压力23MPa,均质时间15min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
步骤5)中还包括调味剂添加,所述调味剂为选自蔗糖、葡萄糖、山梨糖醇和甘露糖醇的混合物。工艺流程请参看图1-3所示。
米醋为9°纯粮米醋。
步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。
实施例5
本实施例的具有降三高病症功能的复方醋蛋液,其中:通过将包括下述组分的原料加工制备而成:
功能性组分:所述功能性组分包括第一功能性组分和第二功能性组分:
第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦5:党参8:白术5:茯苓9:炙甘草0.5:黄芪20:丹参7;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚35:龙眼肉25:枸杞子15:绞股蓝30:荷叶20:葛根20:黄精10:益智仁8:山酸枣8:北虫草20;
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为米醋。
本实施例的品质高且可实现规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量9倍水进行回流提取3次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温22℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为77:22:8,于20MPa下均质;将均质后的混合原料于55℃下,杀菌2min,冷却至40℃;在冷却后的混合原料中加入的益生菌菌粉,并于40℃下培养发酵3h;
3)将醋与发酵后的发酵混合液按质量比1.2:1的比例混合,在35℃条件下,放置3天后,用无菌水稀释4倍。
4)水果原液的制作工艺:
a)将果汁加热温度58℃处理3min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于60℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,20min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
在步骤2)中,还包括预处理工艺:所述消毒采用浓度为10mg/kg的氯水中浸泡10min消毒。
步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1: 6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为 3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为 20℃,保持压力20MPa,均质时间10min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
步骤5)中还包括调味剂添加,所述调味剂为选自蔗糖、葡萄糖、乳糖、果糖的混合物。
米醋为9°纯粮米醋。
步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。工艺流程请参看图1-3所示。
实施例6
本实施例的具有降三高病症功能的复方醋蛋液,其中:通过将包括下述组分的原料加工制备而成:
功能性组分:所述功能性组分包括第一功能性组分和第二功能性组分:
第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦12:党参 4:白术3:茯苓4:炙甘草2:黄芪10:丹参6;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚25:龙眼肉30:枸杞子25:绞股蓝15:荷叶12:葛根10:黄精10:益智仁10:山酸枣8:北虫草18;
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为米醋。
本实施例的品质高且可实现规模化生产的具有降三高病症功能的复方醋蛋液的制备方法:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量10倍水进行回流提取5次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温25℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为60:30:10,于20MPa下均质;将均质后的混合原料于80℃下,杀菌30min,冷却至45℃;在冷却后的混合原料中加入的益生菌菌粉,并于45℃下培养发酵6h;
3)将醋与发酵后的发酵混合液按质量比0.5~2:1的比例混合,在35℃条件下,放置2~4天后,用无菌水稀释1~5倍。
4)水果原液的制作工艺:
a)将果汁加热温度58℃处理3min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于60℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,20min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
在步骤2)中,还包括预处理工艺:所述消毒采用75%酒精擦拭或采用浓度为10mg/kg的氯水中浸泡10min消毒。
步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1: 6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为 3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为 40℃,保持压力30MPa,均质时间10-20min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
步骤5)中还包括调味剂添加,所述调味剂为选自蔗糖、葡萄糖、乳糖、果糖、山梨糖醇和甘露糖醇中的一种或几种的混合物。
米醋为9°纯粮米醋。
步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。工艺流程请参看图1-3所示。
上述实施例1-6的具有降三高病症功能的复方醋蛋液用于下述病例后的使用效果如下:
病例1、高血脂类人群,通过对管氏三清扶正醋蛋液的118例服用者,观察随访,其中67例服用一个星期后血脂五项指数明显降低,39例效果显著,11 例有效,1例化验结果无明显变化,但服用者自觉身体轻松。其中一例:男/42 岁/工人服用之前血脂五项指标为总胆固醇(TCH)12.3(正常值为 2.9-6.0mmoL/L),服用一个星期后5.7mmoL/L;低密度脂蛋白-胆固醇(LDL—ch) (正常值为1.03-1.55mmoL/L)3.2,服用一个星期后1.12mmoL/L;甘油三脂(TG) (正常值为0.2-1.2mmoL/L)3.6,服用一个星期后0.83mmoL/L;高密度脂蛋白(HOLP)2.3(正常值为1.0~1.8mmol/L),服用一个星期后1.65。
脂蛋白(α)即LP(α)正常值<300mg/mL,通过以上人群随访观察,得出结论,管氏三清扶正醋蛋液总有效率达到99%以上。
病例2、失眠多梦人群,根据对管氏三清扶正醋蛋液的62名服用者近半年的观察随访,其中29名长期失眠症的具有明显改善,31神经衰弱多梦者效果显著,2名头疼头晕引起的失眠,已彻底治愈,通过以上数据,得出结论管氏三清扶正醋蛋液对此类症状有效率接近100%。
病例3、便秘类人群,根据对近期3个月对管氏三清扶正醋蛋液16例的观察随访,其中12人中度便秘的人恢复正常,排便质量明显提高,3例重度便秘的人效果显著,1例肠道宿便的已治愈。由此得出管氏三清扶正醋蛋液对肠道干燥,菌群紊乱的人群,有效率100%。
病例4、痛风类人群,依据对近期6个月对22名服用管氏三清醋蛋液服用者观察,12名有痛风症状服用者,自服用后未曾发作,其中3名急性发作的服用者,服用当天有明显减轻的效果,7名化验尿酸指数半年内恢复正常。由此证实管氏三清扶正醋蛋液对痛风有效。
病例5、心脑血管类人群,根据对17名管氏三清扶正醋蛋液服用者观察随访,有7名多发性轻微腔梗的患者反映,头疼头晕症状改善明显,5名有心慌心悸的服用者反映服用1个月症状明显好转,其中3名记忆力减退患者已恢复正常,另外两名心前区阵发性疼痛的患者,自服用后未曾发作。由此证明管氏三清扶正醋蛋液对此类人群有效。
病例6、偏瘫后遗症人群:依据1年内对57名服用管氏三清扶正醋蛋液者观察随访,发现32名偏瘫服用者患侧肢体活动范围明显好转,且肢体发力比服用前明显增强。15名服用者睡眠改善,排便改善,其余8名有不同程度的改善。其中两名38岁坚持服用者,已能自理。自此得出管氏三清扶正醋蛋液对此类人群效果显著。
Claims (10)
1.具有降三高病症功能的复方醋蛋液,其特征在于:通过将包括下述组分的原料加工制备而成:
功能性组分、水果、禽蛋、醋、益生菌和奶制品;
其中,所述功能性组分包括苦荞麦、党参、白术、茯苓、炙甘草、黄芪和丹参、桑葚、龙眼、枸杞、绞股蓝、荷叶、葛根、黄精、益智仁、枣和虫草。
2.根据权利要求1所述的具有降三高病症功能的复方醋蛋液,其特征在于:通过将包括下述组分的原料加工制备而成:
功能性组分:所述功能性组分包括第一功能性组分和第二功能性组分:所述第一功能性组分包括选自苦荞麦、党参、白术、茯苓、炙甘草、黄芪和丹参中的一种或多种的混合物;所述第二功能性组分包括选自桑葚、龙眼肉、枸杞子、绞股蓝、荷叶、葛根、黄精、益智仁、山酸枣和北虫草中的一种或多种的混合物;
水果:所述水果为包括选自苹果、山楂、橙子和沙棘中的一种或几种的混合物;
禽蛋:所述禽蛋为包括选自鸭蛋、鸡蛋和/或鹌鹑蛋中的一种或两种的混合物;
醋:所述醋为包括选自香醋、水果醋和/或米醋中的一种或两种的混合物;
益生菌:所述益生菌为选自乳酸菌和双歧杆菌中的一种或两种的混合物;及
奶制品:所述奶制品为选自牛奶和羊奶中的一种或两种的混合物。
3.根据权利要求1所述的具有降三高病症功能的复方醋蛋液,其特征在于:
所述第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦(5-15):党参(1-8):白术(0.5-5):茯苓(1-9):炙甘草(0.5-5):黄芪(5-20):丹参(1-10);
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚(20-35:龙眼肉(25-40):枸杞子(15-45):绞股蓝(10-30):荷叶(5-20):葛根(5-20):黄精(5-20):益智仁(5-20):山酸枣(2-12):北虫草(10-30);
所述水果为沙棘;所述禽蛋为鹌鹑蛋;所述醋为米醋。
4.根据权利要求2所述的具有降三高病症功能的复方醋蛋液,其特征在于:
所述第一功能性组分中,按重量百分比计,组分用量配比为:苦荞麦12:党参4:白术3:茯苓4:炙甘草2:黄芪10:丹参6;
所述第二功能性组分中,按重量百分比计,组分用量配比为:桑葚25:龙眼肉30:枸杞子25:绞股蓝15:荷叶12:葛根10:黄精10:益智仁10:山酸枣8:北虫草18。
5.根据权利要求1所述的具有降三高病症功能的复方醋蛋液的制备方法,其特征在于:包括如下步骤:
1)、功能性成分的制备:
将上述按重量百分比计的功能性组分按处方量进行混合,然后于处方中加入处方量总重量8-10倍水进行回流提取2-5次,所得液体使用10万D超滤柱进行超滤,浓缩得到中药复方提取液;
2)醋蛋液原液的制备:
溶解蛋壳:取新鲜禽蛋清洗消毒后,接着将其与醋按质量比1:2:3的比例浸泡于玻璃罐内,浸泡室温20-25℃,密闭浸泡72小时,并保证蛋壳被完全溶解;溶解蛋黄、蛋清:挑破蛋膜,将蛋清、蛋黄、及醋液搅拌混匀,再次浸泡24小时;过滤:过300目筛网,滤掉渣膜,得到淡黄色醋蛋液原液;将搅拌均匀的蛋液、牛奶、白砂糖进行混合,混合的比例为(60~80):(15~30):(5~10),于20MPa下均质;将均质后的混合原料于55~80℃下,杀菌2~30min,冷却至40~45℃;在冷却后的混合原料中加入的益生菌菌粉,并于40~45℃下培养发酵3~6h;
3)将醋与发酵后的发酵混合液按质量比0.5~2:1的比例混合,在25~35℃条件下,放置2~4天后,用无菌水稀释1~5倍。
4)水果原液的制作工艺:
a)将果汁加热温度55~58℃处理1~3min后过滤超滤,灌装机过滤;b)澄清将过滤后的果汁放入离心机:以4000r/min转速离心10min;c)装罐脱气将果汁装入容器内;至于50到60℃水中5min进行脱气,然后旋紧盖子准备杀菌;d)杀菌将封盖后的果汁放入60°的水域中进行加热,10~20min,冷却备用;
5)将步骤1)步骤3)和步骤4)得到的产物混合,二次灭菌后无菌灌装得到成品。
6.根据权利要求5所述的具有降三高病症功能的复方醋蛋液的制备方法,其特征在于:在步骤2)中,还包括预处理工艺:所述消毒采用75%酒精擦拭或采用浓度为10mg/kg的氯水中浸泡10min消毒。
7.根据权利要求5所述的具有降三高病症功能的复方醋蛋液的制备方法,其特征在于:所述步骤5)中还包括食品添加剂的添加:
将山梨酸钾、L-阿拉伯糖按质量比山梨酸钾:L-阿拉伯糖:功能性组分为1:6:800比例混合,再加入300倍山梨酸钾质量的蜂蜜搅拌,混匀,缓慢加入3 倍山梨酸钾质量的羧甲基纤维素钠,搅拌至无明显不溶的羧甲基纤维素钠,静置放置至全部羧甲基纤维素钠溶解,最后按照功能性组分与醋蛋原液质量比为3:5的比例加入醋蛋液原液;均质:将混合后的醋蛋液过高压均质机,温度为20-40℃,保持压力20-30MPa,均质时间10-20min;将上述醋蛋液进行常规灭菌后进行罐装,再进行二次灭菌,即得成品。
8.根据权利要求5所述的具有降三高病症功能的复方醋蛋液的制备方法,其特征在于:所述步骤5)中还包括调味剂添加,所述调味剂为选自蔗糖、葡萄糖、乳糖、果糖、山梨糖醇和甘露糖醇中的一种或几种的混合物。
9.根据权利要求5所述的具有降三高病症功能的复方醋蛋液的制备方法,其特征在于:所述米醋为9°纯粮米醋。
10.根据权利要求5所述的具有降三高病症功能的复方醋蛋液的制备方法,其特征在于:所述步骤3)中水果原液制作工艺中,榨汁程序后,按质量百分比计,加入沙棘汁原液质量的1%的食盐。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810119322.6A CN108552491A (zh) | 2018-02-06 | 2018-02-06 | 具有降三高病症功能的复方醋蛋液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810119322.6A CN108552491A (zh) | 2018-02-06 | 2018-02-06 | 具有降三高病症功能的复方醋蛋液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108552491A true CN108552491A (zh) | 2018-09-21 |
Family
ID=63532236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810119322.6A Pending CN108552491A (zh) | 2018-02-06 | 2018-02-06 | 具有降三高病症功能的复方醋蛋液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108552491A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110140959A (zh) * | 2019-05-30 | 2019-08-20 | 熊吉素 | 一种糖尿病三合一酵素 |
CN111000790A (zh) * | 2019-12-30 | 2020-04-14 | 正大食品(襄阳)有限公司 | 一种亚临界法制备蛋膜素的方法 |
CN111387492A (zh) * | 2020-04-10 | 2020-07-10 | 内蒙古坤华生物科技有限公司 | 一种调节肠胃功能的组合物及其制备方法 |
CN113974040A (zh) * | 2021-11-15 | 2022-01-28 | 杭州裕善源科技有限公司 | 一种保健饮料 |
CN114557430A (zh) * | 2021-11-09 | 2022-05-31 | 唐山共生源生物科技有限公司 | 一种乳酸菌醋蛋液及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040097703A (ko) * | 2003-05-13 | 2004-11-18 | 홍재훈 | 콜레스테롤 저하용 초란 조성물 및 그 제제 |
JP2008054543A (ja) * | 2006-08-30 | 2008-03-13 | Minaminasu Keiran:Kk | 酢卵飲料食品の製造方法及びその製造方法によって得られた酢卵飲料食品 |
CN104115950A (zh) * | 2014-05-15 | 2014-10-29 | 王腾鉴 | 一种降脂、降压、降糖的三降茶 |
CN106360420A (zh) * | 2016-10-21 | 2017-02-01 | 镇江刘恒记食品有限公司 | 一种发酵型醋蛋液的制备方法 |
CN106490508A (zh) * | 2016-10-26 | 2017-03-15 | 内蒙古天奇生物科技有限公司 | 一种具有健脾化湿功能的醋蛋液的制备方法 |
-
2018
- 2018-02-06 CN CN201810119322.6A patent/CN108552491A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040097703A (ko) * | 2003-05-13 | 2004-11-18 | 홍재훈 | 콜레스테롤 저하용 초란 조성물 및 그 제제 |
JP2008054543A (ja) * | 2006-08-30 | 2008-03-13 | Minaminasu Keiran:Kk | 酢卵飲料食品の製造方法及びその製造方法によって得られた酢卵飲料食品 |
CN104115950A (zh) * | 2014-05-15 | 2014-10-29 | 王腾鉴 | 一种降脂、降压、降糖的三降茶 |
CN106360420A (zh) * | 2016-10-21 | 2017-02-01 | 镇江刘恒记食品有限公司 | 一种发酵型醋蛋液的制备方法 |
CN106490508A (zh) * | 2016-10-26 | 2017-03-15 | 内蒙古天奇生物科技有限公司 | 一种具有健脾化湿功能的醋蛋液的制备方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110140959A (zh) * | 2019-05-30 | 2019-08-20 | 熊吉素 | 一种糖尿病三合一酵素 |
CN111000790A (zh) * | 2019-12-30 | 2020-04-14 | 正大食品(襄阳)有限公司 | 一种亚临界法制备蛋膜素的方法 |
CN111000790B (zh) * | 2019-12-30 | 2022-05-13 | 正大食品(襄阳)有限公司 | 一种亚临界法制备蛋膜素的方法 |
CN111387492A (zh) * | 2020-04-10 | 2020-07-10 | 内蒙古坤华生物科技有限公司 | 一种调节肠胃功能的组合物及其制备方法 |
CN114557430A (zh) * | 2021-11-09 | 2022-05-31 | 唐山共生源生物科技有限公司 | 一种乳酸菌醋蛋液及其制备方法 |
CN113974040A (zh) * | 2021-11-15 | 2022-01-28 | 杭州裕善源科技有限公司 | 一种保健饮料 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108552491A (zh) | 具有降三高病症功能的复方醋蛋液及其制备方法 | |
CN106943586A (zh) | 一种男性保健壮阳制剂生产方法 | |
WO2017201877A1 (zh) | 一种红曲葡萄酒及其制备方法 | |
CN1142902A (zh) | 胡萝卜奶茶及制备方法 | |
CN104293552A (zh) | 一种减肥葡萄酒 | |
CN105029553A (zh) | 一种果汁蛋钙中药保健饮料及其制备方法 | |
CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
CN102559460A (zh) | 一种养生酒及其制备方法 | |
CN110093239A (zh) | 一种诺丽配制酒及其制备方法 | |
CN109730222A (zh) | 酵素复合液及其保健饮料 | |
CN108813633A (zh) | 林蛙卵肽粉 | |
CN108690775B (zh) | 养生保健白酒的生产方法与养生保健白酒及其用法 | |
CN106234699A (zh) | 一种清热宣化治疗发热的药茶及制备加工方法 | |
CN109717437A (zh) | 一种解酒复合蜂蜜膏及其制备方法 | |
CN108004090A (zh) | 一种保健药酒及其制备方法 | |
CN106165747A (zh) | 一种治疗中焦虚寒积食胃炎药茶及制备加工方法 | |
CN106173037A (zh) | 一种固脾肾化湿浊治疗前列腺炎的药茶及制备加工方法 | |
CN106234698A (zh) | 一种养阴活血防治功能性震颤综合症的药茶及制备加工方法 | |
CN106173625A (zh) | 一种养阴清肺宁络饮料及制备加工方法 | |
KR101338498B1 (ko) | 대추를 이용한 건강음료 제조방법 및 이에 의해 제조되는 건강음료 | |
CN109172723A (zh) | 一种九味酒及其生产方法 | |
CN111418834A (zh) | 一种蔬菜保健膳食配方及其制备方法 | |
CN113679043A (zh) | 一种安神补脑增强免疫力的桑椹口服液及其制备方法 | |
CN110140959A (zh) | 一种糖尿病三合一酵素 | |
CN109430619A (zh) | 一种莲藕复合型保健饮料及其加工方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180921 |
|
RJ01 | Rejection of invention patent application after publication |